Prof. Christian Kurzeder Breast Cancer Center, University Hospital Basel PD Dr. Marcus Vetter Medical University Clinic, Canton Hospital Baselland

Organisation

Regula Gschwind Breast Cancer Center, University Hospital Basel Spitalstrasse 21, 4031 Basel regula.gschwind@usb.ch

Speakers

Prof. Christian Kurzeder, Breast Cancer Center, University Hospital Basel

PD Dr. Marcus Vetter, Oncology, Hematology & Immunotherapy Medical University Clinic, Canton Hospital Baselland

Prof. Michael Untch, Breast Cancer Center, Helios Klinikum Berlin-Buch

Prof. Hervé Bonnefoi, Bordeaux Institute of Oncology (BRIC)

PD Dr. Khalil Zaman, Breast Cancer Center, Hospitalier Universitaire Vaudois (CHUV)

2 Credits SGGG 2 Credits SGMO

The certificate of participation will be sent to your personal email address after the event (according to the guidelines of the professional societies).





4th Swiss Annual Meeting on HER2 positive Breast Cancer and ADCs

Thursday, April 10, 2025, 17.00-19.00 p.m.

University Hospital Basel Hörsaal 2, B2, 2. Stock/Klinikum 1

Local Symposium & Webinar



Dear colleagues

The emergence of antibody-based therapies has changed our view on Her-2 overexpressing breast cancer, a story of great success that is ongoing. Most recently, HER2 directed ADCs have shown activity in HER2 negative but HER2 low breast cancer patients, and the books on classification of breast cancer need to be rewritten. With all these improvements, also new questions, challenges, and controversies arise.

This symposium has been carefully designed to bring together leading experts in the field of oncology to discuss the latest advancements and challenges in the treatment of breast cancer, with a particular focus on HER2 overexpression and HER2 low expression. Additionally, we aim to broaden the spectrum of ADCs targeting different receptors, further expanding the possibilities for innovative treatment approaches.

The program includes a range of topics that we believe are crucial for the continued education and development of medical professionals dedicated to breast cancer care. Again, we want to present and summarize recent advances and offer a practice-focused education symposium. Eventually, we want to explore and discuss with you current treatment practice and future perspectives for the treatment of early stage and metastatic breast cancer.

We look forward to your participation in what promises to be an enlightening and invigorating day, full of opportunities for learning and discussion.

Best regards

Prof. Christian Kurzeder Breast Cancer Center. University Hospital Basel PD Dr. Marcus Vetter Oncology, Hematology & Immunotherapy Medical University Clinic, Canton Hospital Baselland

Many thanks to our Partner and our Sponsors

healthbook." Partner:

Daiichi-Sankyo **Main Sponsor:**

AstraZeneca

Silver Sponsor:







Bronze Sponsor:



Program

Thursday, April 10, 2025, 17.00 – 19.00 p.m.



17.00–17.05 h	Introduction	Prof. Christian Kurzeder/ PD Dr. Marcus Vetter
17.05–17.25 h	Major Clinical Advancements in ADC Therapy for Breast Cancer: Current Progress and Future Directions	Prof. Michael Untch
17.25–17.35 h	Discussion	
17.35–17.50 h	Emerging Therapies for HER2-Low and Triple negative Breast Cancer with focus on ADCs and Sequencing of ADCs	PD Dr. Marcus Vetter
17.50–17.55 h	Discussion	
17.55–18.10 h	Escalation and de-escalation strategies in Her2 positive and triple negative early breast cancer	Prof. Hervé Bonnefoi
18.10–18.15 h	Discussion	
18.15–18.30 h	Overcoming Resistance to ADC Therapy: Biomarkers, Mechanisms, and Future Innovations	PD Dr. Khalil Zaman
18.30–18.35 h	Discussion	
18.35–18.50 h	Optimizing Toxicity Management of ADCs: Essential Insights for Clinical Practice	Prof. Christian Kurzeder
18.50–18.55 h	Discussion	
18.55–19.00 h	Summary and Discussion	Prof. Christian Kurzeder
ab 19.00 h	Afterwards we would like to invite you to an aperitif	

Registration is required

To attend this event in person (OnSite), please register to: regula.gschwind@usb.ch To attend this event **online**, please register using the following link:



online registration

After registration, the access link will be sent to you automatically bv e-mail.